Is TB-500 Legal in Oregon? Federal Law, State Rules, and How to Get It
HealthRX.com
TB-500 is not FDA-approved or listed for compounding
See the public record for TB-500
At a glance
- What it is / A synthetic seven-amino-acid fragment of thymosin beta-4 [1]
- FDA approval / None, in the US or any country FDA checked [1]
- Compounding list / Not listed; FDA staff recommended against adding it [1][2]
- HHS draft policy / Nonbinding; addresses certain compounders of TB-500 acetate for injection [3][4]
- Sport / WADA bans thymosin-beta-4 and its derivatives, including TB-500, at all times [5][6]
Is TB-500 approved or listed for compounding?
TB-500 is a synthetic, N-acetylated seven-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, and 'TB-500' is a common name, not an official drug name [1]. FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, and no approved product in any country it checked [1].
FDA says a state-licensed pharmacy or physician may compound only with a bulk substance that meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's compounding list [2]. TB-500 meets none of those conditions [1][2]. It appears in none of the three categories on FDA's compounding list for state-licensed pharmacies and physicians, and not on the outsourcing-facility list [7][8][2]. FDA's category 1 policy, under which it generally does not act against qualifying compounders, does not cover it [2]. On FDA's safety-risk page it appears only in the 'nominated but withdrawn' table, and removal from category 2 was not a finding that it is safe [9].
What changed in 2026
FDA staff proposed in a July 2026 briefing document that neither TB-500 free base nor its acetate be added to the compounding list, citing poor characterization, no human data, no evidence of effectiveness for wound healing and immunogenicity risk from injection [1]. The Pharmacy Compounding Advisory Committee voted in favor of adding it on July 23, 2026, against that recommendation; the vote is advice only, and adding it takes formal rulemaking [10][3].
HHS filed a draft policy on October 28, 2026 naming TB-500 among six peptides [3][4]. It covers TB-500 acetate given by subcutaneous or intramuscular injection. HHS says it "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met, for example a single active ingredient, a patient-specific prescription, and a FDA-registered manufacturer with a certificate of analysis [3][4]. The notice says it "does not establish any rights for any person and is not binding on HHS or the public" [3].
What this means in Oregon
The federal picture is the same in Oregon as elsewhere: TB-500 is unapproved, unlisted, and outside the category 1 policy [1][2]. The only document that contemplates pharmacy access is the HHS draft, which is not a final policy and which HHS may revisit [3]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [3]. Whether Oregon adds its own restrictions on selling or possessing TB-500 is a separate question this page does not answer.
Safety and sport
There is no approved dose and no human dosing study of TB-500 [1]. FDA found no human pharmacokinetic data and no nonclinical toxicity studies, and a search of its adverse-event database through March 26, 2025 retrieved no TB-500 reports; safety in humans is unknown [1].
WADA names "Thymosin-beta4 and its derivatives e.g. TB-500" in section S2.3, prohibited at all times in and out of competition, on the 2026 List and the 2027 List [5][6].
Frequently asked questions
Is TB-500 legal in Oregon?
Did an FDA committee vote to allow compounding of TB-500?
Is TB-500 the same as thymosin beta-4?
Is TB-500 banned in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What are the current drug laws in Oregon?
Whether Oregon separately restricts selling or possessing TB-500 is not established. Federally, TB-500 is not FDA-approved and is not on FDA's compounding list, so under federal rules a pharmacy has no listed basis for compounding it.
What are the new Oregon laws for 2026?
No new Oregon laws for 2026 are described. The 2026 changes are federal: on July 23, 2026, the Pharmacy Compounding Advisory Committee voted in favor of adding TB-500 to the compounding list, against FDA staff's recommendation, but the vote is advice only. HHS also filed a draft policy on October 28, 2026, which is nonbinding and not final.
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.